From the anaesthetist's viewpoint, pharmacokinetics of pregnancy, drugs affecting uterine muscle tension and foetal effects of anaesthetic drugs are reviewed.
Two major determinants of the tissue drug concentration are the free plasma concentration and the tissue blood flow. Control of the free plasma concentration can be achieved only if there is an understanding of what processes change it, for which a simple model is of considerable value.
The following parameters will be briefly reviewed: volume of distribution, proteinbinding, clearance, elimination half-life and circulation time. Examples will be given of changes which occur in these parameters in human pregnancy. The physiological changes in pregnancy will be reviewed using data from Hytten and Leitch. I
Volume of Distribution
In the simple model of drug kinetics, the concentration falls after a single intravenous injection due to drug elimination. For many drugs it has been found that the rate of fall of blood concentration is proportional to the blood concentration (i.e. the fall in blood concentration is exponential or first order). If the concentration of such a drug is plotted (on a logarithmic scale) against time, then a straight line is produced ( Figure 2 ). Vd must not be equated with nor confused with any physiological space or volume -it is only part of a mathematical model designed to explain and predict changes in drug concentration. The concept of Vd may be complicated by several factors.
1. If the drug is significantly taken up by poorly perfused tissues then Vd will change with time.' Then due to redistribution, the blood concentration will fall e.g. thiopentone2 or will rise more slowly e.g. halothane. 3 2. If the drug is highly bound to plasma protein, then the Vd will appear to be small, because the total plasma concentration is used for all the calculations e.g. thiopentone and bupivacaine. During pregnancy the following physiological changes occur which may alter the volume of distribution of a drug. On average:
1. plasma volume rises by 30% 2. other body water rises by 30070 3. cardiac output rises by 20% (at term distributed mostly to the uterus, skin and kidneys) 4. body fat stores rise by 3.5 kg (50%). Table 1 compares the volumes of distribution of several drugs in pregnant and non-pregnant women. 
Protein-binding
Quoted values for the plasma concentration of a drug are usually the sum of the free and bound fractions. It is, however, only the free fraction which has therapeutic or toxic activity and which crosses membranes during the establishment of equilibrium.
Interpretation of the ratio of foetal to maternal drug concentrations therefore requires knowledge of the maternal and foetal protein binding, as will be shown in section three of this article, "Foetal Effects". Dissociation of the drug-protein complex is usually rapid and does not limit the rate at which other drug processes occur.
During pregnancy the plasma albumin concentration falls on average by 20070, although the total amount in circulation increases slightly due to the increased plasma volume. The concentration of some other protein fractions increases with pregnancy.
The percentage binding of a drug may vary significantly with concentration over the therapeutic range as shown in Table 2 , i.e. there is an increase in the mass of drug bound to protein, as the total blood concentration rises, but there is a decrease in the bound drug concentration (expressed as a percentage of total blood concentration). Clearance Clearance is an index of how efficiently an organ (e.g. kidney or liver) irreversibly removes a drug from the blood. Clearance is not only a function of the ability of the organ to extract the drug as it passes through, but also of the blood flow to the organ.
The clearance of a drug which is almost completely extracted from the blood during one passage through the eliminating organ is flow limited. Pethidine clearance, for example, depends substantially on liver blood flow.
The clearance of a drug (e.g. diazepam) which is only minimally extracted from the blood during one passage through the eliminating organ is virtually independent of flow. Table 3 compares blood clearances of several drugs in pregnant and non-pregnant women. It is appropriate to consider suxamethonium in this context. Plasma cholinesterase activity falls during pregnancy reaching a minimum on the second to fourth post partum day. Representative data from Blitt, C. et al. 4 are shown in Table 4 . They also showed, however, that the time to recovery of twitch height to 100/0, 50% and 90% of control was not prolonged but was consistently shorter than in non-pregnant women, although the probability that this was due to chance was greater than 0.05. It is therefore likely that some other physiological change of pregnancy (e.g. plasma volume increase) shortens the clinical action of suxamethonium.
During pregnancy there is an increase in the clearance of digoxin, lithium 5 and ampicillin,6 which depend on the glomerular filtration rate for their excretion. This increased clearance may result in sub-therapeutic blood levels during the pregnancy. A reduction in clearance post partum may result in toxicity.
Elimination Half-life
Knowledge of the rate of fall of blood concentration of a drug allows more accurate prediction of the timing and size of subsequent doses required to maintain an effective plasma level.
If Figure 2 is redrawn with a linear concentration scale, then the plot of concentration against time assumes a curve such that equal increments of time elapse while concentration falls by half ( Figure 3 ). This time is called the elimination half-life.
The elimination of a drug is due to metabolism or excretion (or to both). The halflife of a drug may not be a good index of elimination because it is determined by both the clearance and the volume of distribution as shown in Equation 2.
During pregnancy the average increase in glomerular filtration rate is 60%. Changes also occur in liver enzyme capacity but their interpretation is uncertain. Table 5 compares the elimination half-life of several drugs in pregnant and non-pregnant women. The rate of elimination of gaseous anaesthetics by the lungs is likely to increase during pregnancy, due to an increase in alveolar ventilation by 50%, an increase in cardiac output by 20070 and a decrease in functional residual capacity by 20%. It should be remembered that these physiological changes occur in the first trimester when cervical suture insertion, termination of pregnancy and other procedures are performed. Although the distribution of the increased cardiac output alters during pregnancy, it is likely that the combined effect of these changes will be a more rapid approach of blood concentration towards the inspired concentration, especially for the more soluble agents 7 during both uptake and elimination.
Circulation time
Although the simple mathematical model of drug distribution and elimination is useful for the understanding and prediction of blood levels, measurements of physiological parameters are not easily incorporated. One assumption of the mathematical model is instantaneous mixing of the drug within the blood volume. In practice the mixing time varies from five to 10 minutes in normal individuals. Disease and non-basal conditions further influence mixing time. s For many drugs used in anaesthesia, the interval between administration and onset of action is short and complete mixing could not have occurred. Other kinetic parameters are needed to describe their onset of action. Consider a simple model of the arm to brain vessels ( Figure 4 ). The time for a bolus to reach the brain is directly proportional to the flow rate and inversely proportional to the volume of the system as shown in Equation 3 .
Despite the substantial increase in cardiac output of pregnancy, there is no significant change in the arm to brain circulation time. This, along with other evidence, suggests that the central blood volume is also increased.
The peak concentration of a drug at the brain will depend mainly on the degree of mixing of the bolus with blood.
Two determinants of mixing over which the anaesthetist has some control are the rate of injection 9 and the cardiac output. Large variations in cardiac output occur during pregnancy particularly with the pain and contractions of labour. 10 
CONCLUSION
These kinetic parameters, along with body weight are a useful guide to estimation of initial and incremental drug doses. However, accurate prediction for a particular patient is impossible, especially during pregnancy, when a large scatter of values occurs around the mean. The right dose can only be found by giving the drug and carefully observing the clinical response. Then, with a knowledge of kinetic parameters, appropriate increments can be given.
DRUGS AFFECTING UTERINE MUSCLE TONE
Uterine contractions impair uterine blood flow resulting in reduced transfer of drugs, metabolic nutrients and wastes across the placenta. At times it may be desirable to maximise foetal oxygenation, but it is impossible to simultaneously retard placental drug transfer. As soon as the baby is born, prolonged uterine contraction is required to minimize blood loss. Drugs affecting uterine muscle often have unwanted effects on other smooth muscle (e.g. vascular, bronchial and intestinal) and on other tissues (e.g. brain and blood). Those agents which cause relaxation of the uterus will be considered first, then those which cause contraction (oxytocics).
UTERINE RELAXATION

Volatile Agents
To achieve maximum control over alveolar levels, an accurately calibrated vaporizer and a non-rebreathing system are required. Most agents reduce uterine contractility. No significant difference at equal MAC was found in one study (in vitro) between halothane, enflurane and methoxyflurane, II neither was there a significant difference between 0.5 MAC, 1.0 MAC and 1.5 MAC for each agent. Clinical data relating uterine relaxation to halothane is generally indirect and uncontrolled. The amount of blood lost at operation is an indirect measure of uterine relaxation. Inhalation of 0.5 per cent halothane during caesarean section was found by Moir l2 not to increase blood loss. However at therapeutic abortion Cullen et al. I3 found that the addition of 0.5 per cent halothane (alveolar) to thiopentone-pethidine-nitrous oxide anaesthesia, increased the blood loss from 53 ± 6 ml to 286 ± 66 m!.
In our experience, the best agent for rapid uterine relaxation of short duration is amyl nitrite. It has two major advantages: 1. very low blood solubility and hence rapid onset and offset of action. 2. no anaesthetic properties and hence can safely be used in awake patients. Reliable results can be achieved by crushing the standard 0.2 ml ampoule of amyl nitrite in the reservoir bag of a closed circle system.
It must be remembered that all these agents are significantly taken up by most plastic and rubber anaesthetic tubing and this may contribute to delay in onset and offset of clinical action. Effects on other smooth muscle are clinically obvious with amyl nitrite, viz. hypotension with compensatory tachycardia and venoconstriction. 14 Prominent effects on other body tissues are anaesthesia (halothane) and methaemoglobinaemia (amyl nitrite).
Beta-Adrenergic Agonists
Salbutamol by infusion can be used to inhibit unwanted uterine contractions. 15 Adrenaline in local anaesthetic solutions used for epidural analgesia has been associated with some prolongation of spontaneous labour. 16 This is not a problem now, because the use of adrenaline in these circumstances can be avoided and a long-acting agent used.
Salbutamol is widely used for its action on bronchial smooth muscle. It has been shown that salbutamol decreases uterine blood flow even in the absence of contractions. 17 Other cardiovascular effects limit the usefulness of salbutamol if the dose is increased in attempts to inhibit uterine contractions.
Hypotensive Agents
Sodium nitroprusside produces a reversible dose-related depression of uterine activity in vitro at therapeutic concentrations l8
Metabolic Abnormalities
Oxygen levels and pH must be carefully controlled in vitro for reproducible uterine activity.19 It is likely that similar conditions are necessary during labour. Contractions in the first stage of labour are more powerful in the lateral compared with the supine position 20 when aorta-caval compression is common. Failure of the uterus to contract after an oxytocic may be the result of poor blood supply to the uterus.
STIMULATION OF UTERINE CONTRACTION
"Normal" Blood Loss At Delivery
With vertex presentation, pethidine and nitrous oxide analgesia, and ergometrine at spontaneous delivery, the average blood loss is about 200 ml. A further 150 ml of blood are lost if an epistiotomy is performed. 21 At mid-cavity forceps delivery the blood loss is influenced by the method of analgesia. 8 When general anaesthesia (thiopentone, d-tubocurarine and unsupplemented nitrous oxide) was used Moir and Wallace 22 found the average loss to be 520 ml, with pudendal block 410 ml and with epidural block 270 ml.
At caesarean section blood loss is very variable and averages 750-1000 ml. This loss is approximately halved with epidural anaesthesia. 12 
Ergometrine
Ergometrine causes a marked increase in the resting uterine tone with superimposed irregular contractions. Given as a bolus intravenously it acts in one circulation time and lasts about an hour. The time of onset is slower if given intramuscularly, but this can be shortened by mixture with oxytocin. For routine use there is no advantage in giving more than 250 microgram as the initial dose. 23 Effects on other smooth muscle are common. Ergometrine has alpha-and beta-agonist activity on peripheral blood vessels. 24 Most women get an increase in systolic and diastolic blood pressure. Bradycardia, myocardial ischaemia and pulmonary oedema may occur. Potentiation of these effects will occur in women who are given vasopressor drugs or who have pre-eclampsia or essential hypertension. 25 Acute heart failure may occur after ergometrine in women with a fixed cardiac output (e.g. from stenotic valvular heart disease). Ergometrine should be avoided if possible in these patients, or the dose carefully titrated against response, starting with 50 microgram. Vasodilatation (e.g. with sodium nitroprusside) is the logical treatment of these complications.
Ergometrine markedly increases the barrier pressure of the lower oesophageal sphincter. 26 The frequency of the central emetic action of ergometrine increases from 12 per cent to 46 per cent with epidural analgesia 27 and an alternative oxytocic should be used.
Oxytocin
Oxytocin stimulates uterine contractions indistinguishable from spontaneous contractions. It is used to induce or accelerate labour, and to contract the uterus after delivery. Given as a bolus intravenously it acts in one circulation time, but only lasts a few minutes. For vaginal delivery with epidural analgesia there was, in one study, no difference in the blood loss with five units of synthetic oxytocin (Syntocinon) compared with ergometrine 500 microgramY However at caesarian section it is logical to always continue with an infusion of oxytocin after the initial bolus dose, to minimize the risk of continued bleeding.
Synthetic oxytocin has unexpected alpha-and beta-antagonist actions on peripheral blood vessels. 24 Pronounced but brief hypotension and tachycardia are common. 28 Potentiation of this effect occurs in states of vasoconstriction (e.g. severe pre-eclampsia, dehydration and blood loss).
At doses greater than 45 mU per minute, such as may be used to deliver a molar pregnancy, antidiuretic activity of oxtocin is maximal and equals that of vasopressin. 29 Hyponatraemia, cerebral oedema and fitting may result from prolonged administration of oxytocin at this rate, particularly if given in an excessive volume of 5 per cent dextrose solution. Regular measurement of urine output and conscious state are necessary under these conditions. Serum sodium estimation may also be indicated. No more than maintenance volumes of sodium-containing fluid should be used for the infusion.
Prostaglandin
Prostaglandin F2a and E2 are used to induce and augment labour. 30 Stimulation of gastrointestinal and bronchial smooth muscle also occurs resulting in nausea, vomiting, diarrhoea and dyspnoea which may be severe in accidental overdose. Hypertension is not a clinical problem. Some anticoagulant activity occurs.
FOETAL EFFECTS OF DRUGS
The potential effect of drugs and other exogenous substances on the foetus depends on the timing of exposure, and will be considered under early and late gestation.
Foetal Drug Effects Early In Pregnancy
Complex multifactorial conditions have to be fulfilled before a drug will produce a congenital malformation. The drug has to be given at an appropriate dosage, at the right moment, to a genetically susceptible embryo. The period in which a dysmorphogenic agent can affect the Anaesthesia and Intensive Care, Va/. VIII, No. 3, August, 1980 development of the human embryo is very short, and is over by the 8th week of pregnancy. Despite the many dysmorphogenic drugs discovered in animals, only in a few cases has it been possible to provide proof of their harmful effects in humans. 3'
The atmosphere of operating theatres contains low concentrations of inhalation anaesthetic agents which may come from both high and low pressure sources. 32 However a causal relationship has not been established between chronic inhalation of low concentrations of inhalational anaesthetic agents, and an increased incidence of spontaneous abortion, an altered sex ratio, nor an increased incidence of foetal malformations. 33 It is, nevertheless, reasonable to clean up the theatre environment provided that the hazards of doing so are no greater than the hazards we are trying to avoid, and that the cost is not excessive.
Anaesthesia, or exposure to any other drugs should not occur in early pregnancy unless there is a specific and proven benefit to the mother or foetus. 3l
Foetal Drug Effects Late in Gestation
A major function of the placenta is to facilitate exchange of molecules between mother and foetus, usually by diffusion, according to Fick's law. Neither histologically nor functionally is there a barrier to this exchange. The differences between drugs, in the rates of transfer across the placenta, are determined by their physico-chemical properties. Three major factors need to be considered when interpreting the foetomaternal drug concentration ratio. The first is the site of sampling of foetal and maternal blood. The second is the difference between the maternal and foetal protein binding of drugs, or blood-gas solubility of volatile agents. The third factor is the time interval between maternal exposure and the sampling of maternal and foetal blood.
(aj Sampling Site
Consideration of the anatomy of the human placenta suggests that the umbilical venous blood comes into equilibrium with maternal uterine venous blood. It is often assumed that the maternal drug concentration in arterial blood, or in venous blood from the arm equals that in the uterine veins. This assumption may not be valid.
For the inhalational agents there is a prolonged arterio-venous gradient due to extensive uptake in the peripheral tissues. Table  6 summarizes available data for these agents.
In the supine position, inferior vena caval compression with compensatory vasoconstriction is a normal occurrence in late pregnancy and aortic compression is also common. This may explain the occasional very low value in an otherwise narrow distribution of foeto-maternal drug ratios (e.g. for thiopentone).34 Sympathetic vasoconstriction in Author Marx, G, et al. 48 Stenger, V. et at. 49 Stenger, V. et al. 49 Latto, 1. et al. 3 Siker, E. et al. 50 Siker, E. et al. 50 FoelO-maternal ratios jor whole blood -gas partition co-ejjicients. 51 Halothane .76 Methoxyflurane 1.07 Cyclopropane 1.20 N 2 0 1.00 the arm resulting from spinal or epidural anaesthesia may also result in a prolonged arterio-venous gradient. 35 
(b) Foetal Protein Binding and Blood-Gas Solubility
It is the unbound fraction of a drug in the maternal blood which comes into equilibrium across the placenta with unbound drug in foetal blood. Concentrations of unbound local anaesthetics appear to equilibrate within minutes across the placenta. 35 Drugs with different degrees of protein-binding in maternal compared with foetal blood will be unequally distributed across the placenta at equilibrium. For example, the foeto-maternal ratio of bupivacaine at equilibrium is 0.24±0.14. 36 Differences in the solubility of some inhalational anaesthetic agents in foetal compared with maternal blood are shown in Table 7 .
(e) Time Interval Between Exposure and Sampling
Despite the widely held belief that muscle relaxants do not cross the placenta to any significant degree, there are several reports of paralysed infants born of mothers paralysed for longer than average times, e.g. with tubocurarine for status epilepticusY
The sensitive techniques now available for the measurement of drug concentrations have helped establish that the more water-soluble, polar drugs merely take longer to reach equilibrium than the lipid-soluble drugs. It has been found for example that the umbilical venous/maternal venous concentration ratio of pancuronium increases with time and in one study was found to equal 0.48 at 30 minutes. 38 The clinical significance of these blood levels in the foetus is unknown.
U sing less sensitive bioassay techniques, rapid placental transfer of alcuronium has been demonstrated. 39 It is claimed that little AH8165 (fazadinium) crosses the placenta,40 but the analytical method used was unable to detect the drug in seven of the 10 mothers at the time of delivery. Suxamethonium given to the mother causes paralysis in infants homozygous for atypical cholinesterase. 41 Foeto-maternal equilibrium occurs within minutes for thiopentone. Data for thiopentone and pethidine are summarized in Table 8 .
(d) Foetal Oxygenation
The physical state of the newborn (e.g. Apgar score, time to spontaneous respiration), has been found, in many studies, to correlate better with foetal biochemical parameters (e.g. pH, base deficit) than with foetal drug levels. The anaesthetist therefore must make every effort to maximize oxygen delivery to the foetus during anaesthesia by preventing aorto-caval compression and hypovolaemia, and by minimizing the mean intrathoracic pressure and the induction-delivery interval. A sound understanding of the physiological and pharmacokinetic changes of pregnancy, of the actions and side effects of drugs affecting uterine muscle tone, and of the fact that, given sufficient time, foeto-maternal equilibrium across the placenta will be reached for any drug, will make obstetric anaesthesia safer for both mother and baby.
